Luer activated device with valve element under tension

Information

  • Patent Grant
  • 8221363
  • Patent Number
    8,221,363
  • Date Filed
    Wednesday, October 18, 2006
    17 years ago
  • Date Issued
    Tuesday, July 17, 2012
    11 years ago
Abstract
A luer activated device includes an inlet adapted to receive a male luer, an outlet associable with a fluid flow system, and a fluid flow path therebetween. The flow path is defined by an elastomeric flow controller extending between the inlet and outlet and maintained in a tensioned state. When a male luer is inserted into the inlet, some of the tension in the flow controller is relieved, allowing the flow path to deform and change in volume. The flow path is adapted such that the change in volume results in no net fluid displacement or minimal positive fluid displacement when the male luer is inserted into the inlet. Other aspects include tensioned flow controllers having a plurality of sealing layers for the inlet and methods of manufacturing valves having a tensioned fluid flow controller.
Description
FIELD OF THE INVENTION

The present invention relates generally to luer activated devices or valves that allow for the bi-directional transfer of fluids to and from medical fluid flow systems.


BACKGROUND OF THE INVENTION

Luer activated devices (LAD) or valves (LAV) are commonly used in association with medical fluid containers and medical fluid flow systems that are connected to patients or other subjects undergoing diagnostic, therapeutic or other medical procedures. A LAD can be attached to or part of a fluid container or a medical fluid flow system to simplify the addition of fluids to or withdrawal of fluids from the fluid flow system.


Within the medical field there are a wide variety of medical fluid flow systems, serving a variety of functions. One of the more common uses of LADs are in association with fluid flow systems that are used for the intravenous administration of fluids, such as saline, antibiotics, or any number of other medically-related fluids, to a patient. These flow systems are commonly referred to as intravenous or “IV” fluid administration sets, and use plastic tubing to connect a phlebotomized subject to one or more medical fluid sources, such as intravenous solution or medicament containers.


Typically, such intravenous administration sets include one or more LADs providing needless access to the fluid flow path to allow fluid to be added to or withdrawn from the IV tubing. The absence of a needle for injecting or withdrawing fluid has the important advantage of reducing the incidence of needle stick injuries to medical personnel. A LAD typically includes a tapered female luer component, such as the inlet into a valve housing, that accepts and mates with a tapered male luer of a medical infusion or aspiration device, such as a needleless syringe or a administration set tubing brand.


There are certain characteristics and qualities of LADs that are highly desirable. For example, the LAD should provide a sufficient microbial barrier for the full service life of the valve. It is desirable that the microbial barrier be conducive to the application of standard aseptic techniques preformed by clinicians during the use of the device. For example, the geometry of the LAD should be such that it is easily swabbable and reduces the potential of entrapping particulates or contaminants that cannot be cleanly swabbed clear prior to use. In addition, the LAD should not permit cross contamination between the male luer and the surfaces of the aseptic fluid path.


Furthermore, it is highly desirable that the LAD be substantially devoid of any interstitial space or any other “dead space” that cannot be flushed, or that such interstitial space be physically isolated from the fluid flow path. Such interstitial space has the potential of providing an environment for undesired microbial growth. In addition, the LAD should have a geometry that allows it to be sufficiently flushed so as to clear the dynamic fluid path and adjacent areas of residual blood or intravenous fluids to prevent undesired microbial growth.


LAD's are commonly used with intravenous catheters that provide access to a patient's vascular system. In such systems, another desirable feature of a LAD is minimal displacement of fluid during insertion and removal of the male luer. In certain situations, it is preferable that the LAD be a neutral/neutral device in that there is zero or only a very slight displacement of fluid during both insertion and removal of the male luer. In other situations it can be desirable for the LAD to produce a positive displacement of fluid from the valve housing during the insertion and removal of the male luer. The LAD also preferably prevents blood reflux into the catheter. Reflux is known to reduce the efficiency of the catheter, contribute to catheter clotting and also contribute to catheter related bloodstream infections.


In most situations it is preferred that the LAD be ergonomically dimensioned to be completely activated by a wide range of ISO compliant male luer lock adaptors. However, there may some instances when the LAD is specifically designed to be activated by a male luer lock that is not ISO complaint. Another desirable characteristic of a LAD is the ability of the LAD to seal against pressure contained within a fluid system to which the LAD is connected. For example, it is desirable to be leak resistance to positive pressures ranging from 10 to 45 psi and to negative pressures or vacuum from 1 to 5 psi. The LAD also preferably has a geometry that allows for easy priming and flushing that does not require any additional manipulations to remove residual air bubbles from the tubing system.


These and other desirable characteristics, which may be used separately or in combination, is preferably present over the full service life of the valve. When used in connection with an IV set or catheter, the LAD may go through many connections and disconnections. It is desirable that the life of an LAD last through upwards to about 100 connections and disconnections or 96 hours of dwell time.


As described more fully below, the fluid access devices of the present invention provides important advances in the safe and efficient administration or withdrawal of medical fluids to or from a fluid flow system.


SUMMARY OF THE INVENTION

In accordance with one aspect of the present invention, a medical valve for the bi-directional transfer of fluid is provided with a valve housing having an inlet adapted for receiving a male luer, an outlet and a passageway therethrough. A fluid flow controller is received within the valve housing and has a valve element fixedly attached to the inlet. The valve element has a resealable aperture for receiving a male luer and sealing the inlet. An extending portion extends away from the valve element and is fixedly attached to the outlet to define a fluid flow path in communication with the aperture and the outlet. The fluid flow controller is maintained in a tensioned state within the valve housing, such that insertion of a male luer into the inlet decreases the tension in at least a portion of the fluid flow controller.


According to another aspect of the present invention, a medical valve for the bi-directional transfer of fluid is provided with a valve housing having an inlet adapted for receiving a male luer. A fluid flow controller associated with the valve housing has a valve element fixedly attached to the inlet in a tensioned state. The valve element has a first sealing layer defining a first resealable aperture, a second sealing layer defining a second resealable aperture, and a channel therebetween and in communication with both apertures. The channel is substantially closed in the tensioned state and open in an untensioned state.


According to yet another aspect of the present invention, a method of manufacturing a medical valve involves providing a fluid flow controller having a valve element and an extending portion defining a fluid flow path. The valve element is fixedly attached to an upper portion of a valve housing so as to seal an inlet of the upper housing portion. The fluid flow controller is stretched away from the inlet and a lower housing portion is placed over the extending portion of the fluid flow controller so that the extending portion extends into an outlet of the lower housing portion. The lower housing portion is fixedly attached to the lower housing portion and a section of the extending portion is fixedly attached to the outlet, thereby maintaining the fluid flow controller in a tensioned state.





BRIEF DESCRIPTION OF THE DRAWINGS

Turning now to a more detailed description of the various embodiments of the present invention illustrated in the attached drawings, of which:



FIG. 1 is a cross-sectional view of one embodiment of a luer activated device of the present invention;



FIG. 2 is a cross-sectional view of the LAD of FIG. 1, with a male luer partially inserted therein;



FIG. 3 is a cross-sectional view of the LAD of FIG. 1, with a male luer fully inserted therein;



FIGS. 4-7 show a method of manufacturing the LAD of FIG. 1;



FIG. 8 is a cross-sectional view of another embodiment of an LAD according to the present invention;



FIG. 9A is a cross-sectional view of the LAD of FIG. 8, with a male luer partially inserted therein;



FIG. 9B is a cross-sectional view of the LAD of FIG. 8, with a male luer fully inserted therein;



FIGS. 10-13 show a method of manufacturing the LAD of FIG. 8;



FIG. 14 is a cross-sectional view of another embodiment of an LAD according to the present invention;



FIG. 15 is a cross-sectional view of the LAD of FIG. 14, with a male luer partially inserted therein;



FIG. 16 is a cross-sectional view of the LAD of FIG. 14, with a male luer fully inserted therein;



FIGS. 17-21 show a method of manufacturing the LAD of FIG. 14;



FIG. 22 is a cross-sectional view of a variation of the LAD of FIG. 14;



FIG. 23 is a cross-sectional view of the LAD of FIG. 22, with a male luer fully inserted therein;



FIG. 24 is a cross-sectional view of a portion of the LAD of FIG. 22 incorporated into a T-site;



FIG. 25 is a cross-sectional view of the device of FIG. 24, with a male luer fully inserted into the T-site; and



FIG. 26 is a cross-sectional view of a portion of the LAD of FIG. 22 incorporated into another T-site.





DETAILED DESCRIPTION OF THE INVENTION

As required, detailed embodiments of the present invention are disclosed herein; however, it is to be understood that the disclosed embodiments are merely exemplary of the invention, which may be embodied in various forms. Therefore, specific details disclosed herein are not to be interpreted as limiting, but merely as a basis for teaching one skilled in the art to variously employ the present invention in virtually any appropriate manner.



FIG. 1 generally illustrates a first embodiment of a luer activated device (LAD) or valve of the present invention, generally designated as 10. The LAD 10 includes a generally tubular valve housing 12 preferably comprised of a rigid material, such as plastic or other suitable material. The LAD 10 is provided as a combination of a joined upper housing portion 14 and a lower housing portion 16. The LAD 10 also includes an inlet 18, an outlet 20, and a passageway 22 defined therebetween. The terms “inlet” and “outlet” are not to be interpreted as limiting the LAD 10 to applications involving fluid flow in a particular direction, e.g., from the inlet 18 to the outlet 20, because LAD's according to the present invention may be used in applications involving fluid flow from the inlet 18 to the outlet 20 or from the outlet 20 to the inlet 18.


The outlet 20 is adapted to be connected to any of a number of fluid flow systems, so the exact configuration of the outlet 20 will vary according to the nature of the fluid flow system to which it is to be connected. For example, the illustrated outlet 20 is suitable for use in connecting the valve 10 to an IV administrative tubing set (not illustrated). In the embodiment of FIG. 1, the outlet 20 includes a skirt 24 defining an internal thread 26, which may be adapted to engage an external thread of the associated fluid flow system (not illustrated). Of course, the outlet 20 may be provided with a different configuration, a different locking system, or without a locking system, depending on the anticipated usage of the valve 10.


The inlet 18 includes an opening 28 adapted to receive a male luer 30 (FIGS. 2 and 3) according to known structure and operation. The inlet 18 and male luer 30 preferably conform functionally to ISO and/or ANSI standards. In general the inlet 18 is unable to conform dimensionally to ISO luer standards as there would be insufficient volume to house the septum displacement upon insertion of a luer tip.


The male luer 30 has a hollow channel 32 defined by a generally tubular wall 34. The wall 34 preferably has a substantially smooth outer surface 36 which is typically cylindrical or conical. The inlet 18 may include external threads 38, in which case a portion of the luer wall 34 may be surrounded by a collar member 40 (FIGS. 2 and 3) having internal threads 42 adapted to removably lock the male luer 30 to the inlet 18. Other locking mechanisms may also be incorporated into LAD's according to the present invention.


By way of example, the collar member 40 and luer wall 34 may be configured to provide a tactile feel when the male luer 30 has been fully engaged to the LAD 10. As shown in shadow in FIG. 3 the luer wall may include some detents 13 which are placed so as to register with one of cavities or openings 11 formed in the collar member 40. To allow the LAD to connect with standard male luers, the detents 13 may be placed lower on the luer wall 34 and the collar member 40 extended to provide the registration.


The inlet 18 fixedly receives a fluid flow controller 44 having a resealable slit or aperture 46 therethrough. The flow controller 44 acts as a microbial barrier between the internal passageway 22 of the LAD 10 and the atmosphere. The flow controller 44 may include a substantially concave upper surface 48 (FIG. 1), which provides a relatively tight seal of the aperture 46. Alternatively, the upper surface 48a may be substantially flat (FIG. 7), such that it can be easily wiped with antiseptic, which aids in preventing contamination during use.


The flow controller 44 is comprised of a first portion or valve element 50, which includes the upper surface 48 and the aperture 46, and a second portion or extending portion 52 (FIG. 1) that extends away from the valve element 50. The extending portion 52 is generally tubular and defines a fluid flow path 54 in communication with the aperture 46 of the valve element 50. The valve element 50 is fixedly attached to the LAD inlet 18, while the extending portion 52 is fixedly attached to the LAD outlet 20, preferably by mechanical means, such as a bushing member 56. The operation of the flow controller 44 is illustrated in FIGS. 2 and 3, and will be described in greater detail herein.


Preferably, the flow controller 44 is molded as a unitary piece, typically from a deformable elastomeric material, such as silicone or rubber or santoprene. The “as-molded” configuration of the flow controller 44 is shown in FIG. 4, with a substantially convex upper surface 48b and an extending portion 52 comprised of a wall 58 having a bulb or bulge 60. The illustrated wall 58 has a generally uniform outer radius, except for the bulge 60, which has an increased outer radius. The bulge 60 affects the flow dynamics of the LAD 10, as will be described in greater detail herein.


It will be seen that the flow controller 44 is significantly shorter in the “as-molded” configuration of FIG. 4, as compared to the condition illustrated in FIG. 1. According to a preferred method of manufacturing the flow controller 44, the flow controller 44 is initially provided in the relatively short “as-molded” condition of FIG. 4, along with a separate upper valve housing portion 14. The valve element 50 is fixedly attached to the LAD inlet 18 to close the opening 28 thereof. This may be done by any of a number of means, which vary according to the materials selected for the flow controller 44 and the upper housing portion 14. These means include, but are not limited to, adhesion or mechanical attachment (e.g., crimping), although the flow controller 44 is preferably overmolded onto the upper housing portion 14. The aperture 46 may be formed in the valve element 50 prior to or after the valve element 50 is secured to the LAD inlet 18. Referring briefly to FIG. 2, the overmolded section attaching the controller 44 and the upper housing portion 14, may be dimensioned to engage the threads of the male luer to provide the desired torque resistance to disengagement per ISO standards.


When the valve element 50 has been secured to the inlet 18, an elongated mandrel or vacuum member 62 is inserted through the aperture 46 and the fluid flow path 54 (FIG. 5). A suction source (not illustrated) is associated with the mandrel 62 and creates a vacuum force that pulls the extending portion 52 inwardly against the mandrel 62. The mandrel 62 is then moved downwardly (in the orientation of FIG. 5) to push the convex upper surface 48b into the LAD inlet 18 and stretch the extending portion 52. In the “fully stretched” condition of FIG. 5, the bulge 60 substantially flattens out against the mandrel 62 and the wall 58 of the extending portion 52 has a generally uniform outer radius. It will be appreciated that the flow controller 44, and in particular the extending portion 52 is in a state of tension in the “fully stretched” condition of FIG. 5.


With the mandrel 62 still in place and providing a suction force, the lower valve housing portion 16 is slid over the extending portion 52 and affixed to the upper housing portion 14 (FIG. 6). A portion of the mandrel 62 and the extending portion 52 remains outside of the lower housing portion 16. A bushing member 56 is affixed to this portion of the extending portion 52, and the mandrel 62 is removed (FIG. 7). When the mandrel 62 has been removed, the flow controller 44 is free to move into an “assembled” condition (FIGS. 1 and 7). The flow controller 44 as a whole shifts upwardly and the upper surface 48 assumes either a concave condition (FIG. 1) or a flat condition (FIG. 7) depending on the magnitude of the original convex curvature (FIG. 4) and the degree of stretching. Forcing the upper surface 48 to fit within the inlet opening 28 forces the valve element into a state of radial compression, which promotes an improved seal of the resealable aperture 46, thereby preventing fluid leakage through the inlet 18. The bushing member 56 constrains the extending portion 52, thereby maintaining it in a state of tension, and preventing it from returning to the “as-molded” condition of FIG. 4. From FIG. 7, it will be seen that the fluid flow path 54 is isolated from the surrounding LAD passageway 22 to define the sole path for fluid moving through the LAD 10.


In an alternate embodiment, the extending portion 52 may be directly attached to the lower valve housing portion 52 by over-molding.


Turning now to the operation of the LAD 10, a male luer 30 is inserted into the inlet 18 and through the aperture 46 (FIG. 2). If desired, the aperture 46 or the male luer 30 may be lubricated for ease of insertion and removal. The male luer 30 deforms the flow controller 44 and relieves some of the tension in the extending portion 52. On account of the shape memory of the elastomeric material, this reduction in tension allows the bulge 60 to reemerge and expand outwardly into the surrounding passageway 22, thereby defining a first volume V of the fluid flow path 54.


The male luer 30 is further inserted into the aperture 46 until the aperture 46 completely opens and allows a portion of the male luer 30 to move into the extending portion 52. The outer radius of the male luer 30 is larger than the inner radius of the fluid flow path 54, which causes the portion of the wall 58 between the bulge 60 and the male luer 30 to bend outward into a generally frusto-conical shape defining a fluid reservoir 64 (FIG. 3). When the fluid reservoir 64 has been established and the male luer 30 is fully inserted, a second volume V′ is defined.


The difference between the first volume V (FIGS. 1 and 2) and the second volume V′ (FIG. 3) determines the magnitude of the fluid displacement when the male luer 30 is inserted and removed, and that difference is determined by the configuration of the bulge 60. Reflux of fluid into the male luer 30 can lead to a number of problems, such as contamination, so it may be preferred for the bulge 60 to be adapted such that the difference between the first volume V and the second volume V′ is minimized. In one embodiment, the bulge 60 is adapted such that the first volume V is substantially equal to the second volume V′, which ideally creates a neutral fluid displacement, thereby substantially eliminating fluid reflux when the male luer 30 is inserted or removed. If the volumes V and V′ cannot be practicably equated, then preferably the bulge 60 is adapted such that the second volume V′ is only slightly smaller than the first volume V, which results in a minor positive fluid displacement as the male luer 30 is inserted into the LAD 10 and a minor negative fluid displacement as the male luer 30 is removed from the LAD 10.



FIG. 8 illustrates another LAD 10a according to the present invention. The LAD 10a of FIG. 8 generally conforms to the foregoing description of the embodiment of FIG. 1, except it includes a restrictor member 66 mounted within the valve housing 12. The restrictor member 66 acts as a second or auxiliary resealable aperture, as will be described in greater detail herein.


As with the embodiment of FIG. 1, the flow controller 44a is preferably molded as a unitary piece, typically from a deformable elastomeric material, such as silicone or rubber or santoprene. With the flow controller 44a in an “as-molded” configuration, the valve element 50 is secured to the LAD inlet 18 (FIG. 10) to close the opening 28 thereof. This may be done by any of a number of means, which vary according to the materials selected for the flow controller 44a and the upper housing portion 14. These means include, but are not limited to, adhesion or mechanical attachment (e.g., crimping), although the flow controller 44a is preferably overmolded onto the upper housing portion 14. In FIG. 10, the extending portion 52 of the flow controller 44a is illustrated without a bulge, but a bulge may also be provided without departing from the scope of the present invention.


When the valve element 50 has been secured to the inlet 18, an elongated mandrel or vacuum member 62 is inserted through the aperture 46 and the fluid flow path 54 (FIG. 11). A suction source (not illustrated) is associated with the mandrel 62 and creates a vacuum force that pulls the extending portion 52 inwardly against the mandrel 62. The mandrel 62 is then moved downwardly (in the orientation of FIG. 11) to push the convex upper surface 48b into the LAD inlet 18, stretch the extending portion 52, and maintain the flow controller 44a in a state of tension.


With the mandrel 62 still in place and providing a suction force, the restrictor member 66 is slid over the extending portion 52 and into the position of FIG. 11. In the illustrated embodiment, the restrictor member 66 has an annular rim 68 adapted to abut a shoulder 70 of the upper housing portion 14. A generally tubular portion 72 extends upwardly from the rim 68 and terminates in an inwardly extending upper flange 74. In a relaxed condition (FIG. 8), the flange 74 defines an opening 76 smaller than the diameter of the extending portion 52 to compress and close the fluid flow path 54, but the presence of the mandrel 62 widens the opening 76 into an open condition (FIG. 11). The profile of the opening 76 may vary, provided that it is adapted to close the fluid flow path 54 in the relaxed condition of FIG. 8 and to allow passage of the fluid flow path 54 in the open condition of FIG. 11.


As described in greater detail herein, the flange 74 has the tendency to resiliently return to the relaxed condition when the mandrel 62 is removed from the LAD 10a. Accordingly, the flange 74 is preferably comprised of a material more rigid than the elastomeric material of the flow controller 44a (to pinch the fluid flow path 54 closed), but sufficiently pliable to move between the relaxed condition of FIG. 8 and the open condition of FIGS. 9B and 11. Suitable materials for the flange 74, and preferably the entire restrictor member 66, include rubber, silicone, polyisoprene, HDPE and polyurethane It will be seen from the following description that the restrictor member 66 may be provided in virtually any configuration, provided that it includes means for holding it in place within the LAD 10a and means for resiliently compressing a section of the fluid flow path 54 into a closed position (FIGS. 8 and 9A).


When the restrictor member 66 has been properly positioned within the upper housing portion 14, the lower valve housing portion 16 is slid over the extending portion 52 and affixed to the upper housing portion 52 (FIG. 12). Preferably, the lower housing portion 16 includes an element, illustrated in FIG. 12 as an upwardly extending annular lip 78, which abuts the restrictor member rim 68 and maintains the restrictor member 66 in place. However, other means for maintaining the restrictor member 66 in place within the housing 12 may be used without departing from the scope of the present invention.


A portion of the mandrel 62 and the extending portion 52 remains outside of the lower housing portion 16. A bushing member 56 is affixed to this portion of the extending portion 52 (FIG. 13), and the mandrel 62 is removed (FIG. 8). When the mandrel 62 has been removed, the flow controller 44a is free to move into an “assembled” condition (FIG. 8), according to the foregoing description of the embodiment of FIG. 1. Additionally, the flange 74 of the restrictor member 66 resiliently returns to its relaxed condition, thereby decreasing the size of the opening 76 and pinching closed a section of the fluid flow path 54.


Turning now to the operation of the LAD 10a, a male luer 30 is partially inserted into the inlet 18 and through the aperture 46 (FIG. 9A). The male luer 30 opens the aperture 46, but not the opening 76 of the restrictor member 66, so flow through the LAD inlet 18 remains closed (FIG. 9A). Hence, it will be seen that the restrictor member 66 acts as a secondary or auxiliary sealing element that prevents fluid flow through the inlet 18 when the male luer 30 is only partially inserted. As the male luer 30 is further inserted into the inlet 18, it engages the section of the fluid flow path 54 closed by the restrictor member 66 and forces the restrictor member 66 into the open condition of FIG. 9B. In the condition of FIG. 9B, fluid flow through the LAD 10a may begin. If the extending portion 52 includes a bulge (not illustrated), the fluid displacement upon inserting and removing the male luer 30 will be governed according to the foregoing description of the embodiment of FIG. 1.


Similarly upon withdrawal of the male luer 30, as the male luer is withdrawn the male luer no longer engages the section of the fluid flow path 54 adjacent the restrictor member 66 and the restrictor member then closes the flow path. Further withdrawal of the male luer will create a vacuum condition in the flow path 54 which pulls fluid from within the male luer. This reduces aersolization of fluid from the male luer tip.



FIG. 14 illustrates yet another LAD 10b according to the present invention. The LAD 10b of FIG. 14 generally conforms to the foregoing description of the embodiment of FIG. 1, except it includes a modified valve element 80. The modified valve element 80 provides a second or auxiliary resealable aperture 82, similar to the embodiment of FIG. 8, but it may be preferred for some applications because it eliminates the potential non-flushable “dead space” between the upper and lower sealing elements, as described in greater detail herein.


As with the embodiment of FIG. 1, the flow controller 44b is preferably molded as a unitary piece (FIG. 17), typically from a deformable elastomeric material, such as silicone or rubber or santoprene. The modified valve element 80 includes an upper surface or first sealing layer 48 defining a first resealable aperture 46 adapted to receive a male luer 30 (FIG. 15). In the illustrated embodiment, a skirt 84 extends downwardly from the outer perimeter of the first sealing layer 48. A second sealing layer 86 is spaced from the first sealing layer 48 and includes a rim 88 comparable in structure and operation to the restrictor member rim 68 of the embodiment of FIG. 8. The rim 88 defines a second resealable aperture 82 adapted to receive a male luer 30 (FIG. 16) and preferably coaxial with the first aperture 46. The first and second apertures 46 and 82 are joined by a channel 90. As shown in FIG. 17, the channel 90 is preferably at least partially open in the “as-molded” configuration. The flow controller 44b is illustrated in FIG. 17 with a flat upper surface 48 and a bulge 60, but it will be appreciated from the following description that the upper surface 48 may be substantially convex in the “as-molded” configuration and/or the extending portion 52 may be provided without the bulge 60.


With the flow controller 44b in an “as-molded” configuration, the modified valve element 80 is secured to the LAD inlet 18 (FIG. 18) to close the opening 28 thereof. This may be done by any of a number of means, but is preferably achieved by pushing the upper surface 48 upward through the inlet 18 until the skirt 84 seats within a ledge or shelf 92 of the inlet 18 by a friction fit. Preferably, the upper surface 48 is slightly larger than the inlet 18, such that the upper surface 48 is seated with an interference fit that results in a radial compression that aids in more tightly sealing the first aperture 46.


When the first sealing layer 48 is securely seated, the rim 88 is positioned to abut a shoulder 70 of the upper housing portion 14. The rim 88 may be affixed to the shoulder 70 by a variety of means, depending on the material selected for the housing upper portion 14 and the flow controller 44b. Suitable means may include welding, adhesion, and a press fit with the lower housing portion 16, as described in greater detail herein.


Preferably, the distance between the top of the upper surface 48 and the rim 88 is less than the height of the inlet 18, such that the channel 90 must be stretched to properly position the first and second sealing layers 48 and 86. FIG. 18 shows that a channel 90 in such a state of tension will deform to be substantially closed, along with the first aperture 46 and the second aperture 82. Stretching the channel 90 may cause the first and/or second sealing layers to assume a generally concave configuration (not illustrated) that imparts a radial compression on the associated apertures and aids in maintaining the inlet 18 in a sealed condition.


When the modified valve element 80 has been secured to the inlet 18, an elongated mandrel or vacuum member 62 is inserted through the apertures 46 and 82, the channel 90, and the fluid flow path 54 (FIG. 19). A suction source (not illustrated) is associated with the mandrel 62 and creates a vacuum force that pulls the extending portion 52 and bulge 60 inwardly against the mandrel 62. The mandrel 62 is then moved downwardly (in the orientation of FIG. 20) to stretch the extending portion 52 and maintain the flow controller 44b in a state of tension.


With the mandrel 62 still in place and providing a suction force, the lower housing portion 16 is slid over the extending portion 52 and affixed to the upper housing portion 14 (FIG. 21). Preferably, the lower housing portion 16 includes an element, illustrated in FIG. 21 as an upwardly extending annular lip 78, which compresses the second sealing layer rim 88 and maintains the second sealing layer 86 in place. This may be done instead of or in addition to welding or otherwise securing the rim 88 to the shoulder 70 in the condition of FIG. 18. However, in comparison to the restrictor member rim 68 of FIG. 8, the second sealing layer 86 is relatively flexible, so it may be preferred to use two joinder means (e.g., welding and a compression relationship) to ensure that the second sealing layer 86 is securely maintained within the LAD housing 12.


A portion of the mandrel 62 and the extending portion 52 remains outside of the lower housing portion 16. A bushing member 56 is affixed to this portion of the extending portion 52 (FIG. 21), and the mandrel 62 is removed (FIG. 14). When the mandrel 62 has been removed, the flow controller 44b is free to move into an “assembled” condition (FIG. 14), according to the foregoing description of the embodiment of FIG. 1. Additionally, the channel 90 and the second aperture 82 will resiliently close to seal the inlet 18, along with the first aperture 46.


Turning now to the operation of the LAD 44b, a male luer 30 is partially inserted into the inlet 18 and through the first aperture 46 (FIG. 15). The male luer 30 opens the aperture 46 and at least a portion of the channel 90, but not the second aperture 82, so flow through the LAD inlet 18 remains closed. Hence, it will be seen that the second sealing layer 86 acts as a secondary or auxiliary sealing element that prevents fluid flow through the inlet 18 when the male luer 30 is only partially inserted.


As the male luer 30 is further inserted into the inlet 18, it continues to deform the flow controller 44b, which causes the bulge 60 to reemerge, and opens the second aperture 82 (FIG. 16). In the condition of FIG. 16, fluid flow through the LAD 10b may begin. Depending on the nature of the bulge 60 and the resulting fluid reservoir 64, insertion or removal of the male luer 30 will result in a positive, negative, or neutral fluid displacement, according to the foregoing description of the embodiment of FIG. 1.


It will be appreciated that the embodiment of FIG. 8 similarly provides a second sealing element (the restrictor member opening 76). However, the embodiment of FIG. 14, which provides a substantially closed channel 90 between the upper and lower sealing layers 48 and 86, may be preferred for certain applications.


The flow controller 44b of FIG. 14 may be modified by removing the extending portion 52 and leaving only the valve element 80, as shown in FIGS. 22-26. The resulting flow controller 44c may be incorporated as a valve of any of a number of devices, including LAD's as described herein (FIGS. 22 and 23) and T-sites (FIGS. 24-26). Such a flow controller 44c may be preferred to known single or double slit septum-type valves, because there are two separate sealing layers 48 and 86, along with a channel 90 therebetween that is substantially closed in a relaxed condition (FIGS. 22, 24, and 26) to prevent the creation of a “dead space.”


Referring in particular to FIG. 26, flow flows through the channel formed by the housing in a path which causes any air present in the injection site to be displaced out of the housing. This provides a self flushing feature to the valve.


While the present invention has been described in terms of certain preferred and alternative embodiments for purposes of illustration, it is not limited to the precise embodiments shown or to the particular features, shapes or sizes illustrated. A variety of changes may be made without departing from the present invention as defined by the appended claims.

Claims
  • 1. A medical valve for the bi-directional transfer of fluid comprising: a valve housing having an inlet adapted for receiving a male luer, an outlet and a passageway therethrough; anda fluid flow controller received within the valve housing, said fluid flow controller having a valve element fixedly attached to said inlet, said valve element having a resealable aperture for receiving the male luer and sealing the inlet, andan extending portion extending away from the valve element and fixedly attached to said outlet, said extending portion defining (i) a fluid flow path in communication with said aperture and said outlet (ii) a generally tubular wall, and (iii) a bulge,wherein (a) said fluid flow controller is maintained in a tensioned state within the valve housing, (b) the bulge has a radius larger than a radius of the tubular wall in an untensioned state, and substantially the same radius as the radius of the tubular wall in the tensioned state, and (c) insertion of the male luer into the inlet (1) decreases the tension in at least a portion of the fluid flow controller, (2) changes a volume of said fluid flow controller, and (3) causes the bulge to radially expand to define a fluid reservoir.
  • 2. The medical valve of claim 1, wherein said change in volume results in substantially no fluid displacement when the male luer is inserted or removed from the inlet.
  • 3. The medical valve of claim 1, wherein said change in volume results in a positive displacement of fluid as the male luer is inserted into the inlet.
  • 4. The medical valve of claim 1, wherein the valve element of the fluid flow controller includes a first seating layer defining a first aperture, a second sealing layer defining a second aperture, and a channel therebetween and in communication with said apertures, wherein said channel is substantially closed in a tensioned state and open in an untensioned state.
  • 5. The medical valve of claim 1 in which at least a portion of the fluid flow controller is overmolded onto the valve housing.
  • 6. The medical valve of claim 1 in which at least a portion of the fluid flow controller is mechanically attached to the valve housing.
  • 7. The medical valve of claim 1, further including a restrictor member that resiliently closes a section of the fluid flow path, said restrictor member adapted to open said section of the fluid flow path to open when the male luer is inserted into the fluid flow controller.
  • 8. The medical valve of claim 7 in which the restrictor member compresses the extending portion to close the section of the fluid flow path.
  • 9. The medical valve of claim 8 in which the restrictor member includes an opening and said extending portion of the fluid controller extends through said opening.
  • 10. A medical valve comprising: a valve housing having (i) an inlet adapted for receiving a male luer,(ii) an upper housing portion, and(iii) a lower housing portion, the lower housing portion defining an outlet; anda fluid flow controller associated with the valve housing, the fluid flow controller having (i) an extending portion defined by a generally tubular wall and a bulge, the extending portion fixedly attached to the outlet in a tensioned state, and(ii) a valve element fixedly attached to said inlet in the tensioned state,wherein (a) the extending portion defines a fluid flow path, and (b) the bulge has a larger radius than a radius of the tubular wall in an untensioned state and substantially the same radius as the radius of the tubular wall in the tensioned state,said valve element having (i) a first sealing layer defining a first resealable aperture,(ii) a second sealing layer defining a second resealable aperture,wherein (a) a portion of the second sealing layer is compressed between the upper housing portion and the lower housing portion to attach the second sealing layer to the housing, (b) the extending portion extends away from the second sealing layer, and (c) the fluid flow path is in communication with the second aperture and the outlet, and(iii) a channel therebetween and in communication with said apertures, wherein said channel is substantially closed in the tensioned state and open in the untensioned state,wherein insertion of the male luer into the inlet (a) changes a volume of the fluid flow path, and (b) causes the bulge to radially expand to define a fluid reservoir.
  • 11. The medical valve of claim 10 in which the tension in the channel causes at least one of the first and second sealing layers to have a concave configuration.
  • 12. The medical valve of claim 10 in which the first sealing layer is attached to the valve housing by an interference fit.
  • 13. The medical valve of claim 10 in which the first sealing layer includes a downwardly extending skirt adapted to form a friction fit with the valve housing to attach the first sealing layer to the housing.
  • 14. The medical valve of claim 10, wherein said change in volume results in substantially no fluid displacement when the male luer is inserted or removed from the inlet.
  • 15. The medical valve of claim 10, wherein said change in volume results in a positive displacement of fluid as the male luer is inserted into the inlet.
US Referenced Citations (461)
Number Name Date Kind
4176588 Baron Dec 1979 A
4334551 Pfister Jun 1982 A
4413462 Rose Nov 1983 A
4475548 Muto Oct 1984 A
4691929 Neumaier et al. Sep 1987 A
4928212 Benavides May 1990 A
4943896 Johnson Jul 1990 A
4946445 Lynn Aug 1990 A
4964855 Todd et al. Oct 1990 A
4973443 Larson et al. Nov 1990 A
4998713 Vaillancourt Mar 1991 A
4998927 Vaillancourt Mar 1991 A
5009490 Kouno et al. Apr 1991 A
5019325 Larson et al. May 1991 A
5046456 Heyman et al. Sep 1991 A
D321250 Jepson et al. Oct 1991 S
D321251 Jepson et al. Oct 1991 S
5064416 Newgard et al. Nov 1991 A
5065783 Ogle, II Nov 1991 A
5100394 Dudar et al. Mar 1992 A
5114408 Fleischhaker et al. May 1992 A
5122123 Vaillancourt Jun 1992 A
5135489 Jepson et al. Aug 1992 A
5154703 Bonaldo Oct 1992 A
5158554 Jepson et al. Oct 1992 A
5171234 Jepson et al. Dec 1992 A
5188620 Jepson et al. Feb 1993 A
5199947 Lopez et al. Apr 1993 A
5201717 Wyatt et al. Apr 1993 A
5203775 Frank et al. Apr 1993 A
5211638 Dudar et al. May 1993 A
5242393 Brimhall et al. Sep 1993 A
5242425 White et al. Sep 1993 A
5242432 DeFrank Sep 1993 A
5251873 Atkinson et al. Oct 1993 A
5256155 Yerlikaya et al. Oct 1993 A
5269763 Boehmer et al. Dec 1993 A
5269771 Thomas et al. Dec 1993 A
5280876 Atkins Jan 1994 A
5290254 Vaillancourt Mar 1994 A
5295657 Atkinson Mar 1994 A
5295658 Atkinson et al. Mar 1994 A
5312377 Dalton May 1994 A
5323264 Kato Jun 1994 A
5324270 Kayan et al. Jun 1994 A
5344414 Lopez et al. Sep 1994 A
5360413 Leason et al. Nov 1994 A
5401245 Haining Mar 1995 A
5402982 Atkinson et al. Apr 1995 A
5411499 Dudar et al. May 1995 A
5417673 Gordon May 1995 A
5470319 Mayer Nov 1995 A
5487731 Denton Jan 1996 A
5514109 Mollenauer et al. May 1996 A
5533708 Atkinson et al. Jul 1996 A
5540661 Tomisaka et al. Jul 1996 A
5549566 Elias et al. Aug 1996 A
5549651 Lynn Aug 1996 A
5556388 Johlin, Jr. Sep 1996 A
5578059 Patzer Nov 1996 A
5602016 Isogai et al. Feb 1997 A
5609584 Gettig et al. Mar 1997 A
5616129 Mayer Apr 1997 A
5616130 Mayer Apr 1997 A
5676346 Leinsing Oct 1997 A
5677141 Isogai et al. Oct 1997 A
5685866 Lopez Nov 1997 A
5690612 Lopez et al. Nov 1997 A
5695466 Lopez et al. Dec 1997 A
5699821 Paradis Dec 1997 A
5700248 Lopez Dec 1997 A
5730418 Feith et al. Mar 1998 A
5738663 Lopez Apr 1998 A
5773272 Isogai et al. Jun 1998 A
RE35841 Frank et al. Jul 1998 E
5788675 Mayer Aug 1998 A
5797897 Jepson et al. Aug 1998 A
5820601 Mayer Oct 1998 A
5836923 Mayer Nov 1998 A
5865807 Blake, III Feb 1999 A
5873862 Lopez Feb 1999 A
5901942 Lopez May 1999 A
5928204 Lopez Jul 1999 A
5957898 Jepson et al. Sep 1999 A
5967490 Pike Oct 1999 A
5971965 Mayer Oct 1999 A
RE36587 Tanaka et al. Feb 2000 E
6019748 Lopez Feb 2000 A
6029946 Doyle Feb 2000 A
6036171 Weinheimer et al. Mar 2000 A
6039302 Cote, Sr. et al. Mar 2000 A
RE36661 Tanaka et al. Apr 2000 E
6048335 Mayer Apr 2000 A
6089541 Weinheimer et al. Jul 2000 A
6113068 Ryan Sep 2000 A
6132403 Lopez Oct 2000 A
6132404 Lopez Oct 2000 A
6146396 Konya et al. Nov 2000 A
6152900 Mayer Nov 2000 A
6162251 Kredovski Dec 2000 A
6171287 Lynn et al. Jan 2001 B1
6177037 Mayer Jan 2001 B1
6183448 Mayer Feb 2001 B1
6187476 Pyun et al. Feb 2001 B1
6210624 Mayer Apr 2001 B1
6228069 Barth et al. May 2001 B1
6245048 Fangrow, Jr. et al. Jun 2001 B1
6261268 Mayer Jul 2001 B1
6261282 Jepson et al. Jul 2001 B1
6290206 Doyle Sep 2001 B1
6299132 Weinheimer et al. Oct 2001 B1
6325782 Lopez Dec 2001 B1
6341802 Matkovich Jan 2002 B1
6344033 Jepson et al. Feb 2002 B1
6355023 Roth et al. Mar 2002 B1
6364869 Bonaldo Apr 2002 B1
6374876 Bynum Apr 2002 B2
6383168 Landau et al. May 2002 B1
6390120 Guala May 2002 B1
6390130 Guala May 2002 B1
6394983 Mayoral et al. May 2002 B1
6394992 Sjoholm May 2002 B1
6402723 Lampropoulos Jun 2002 B1
6408897 Laurent et al. Jun 2002 B1
6409707 Guala Jun 2002 B1
6409708 Wessman Jun 2002 B1
6423053 Lee Jul 2002 B1
6428520 Lopez et al. Aug 2002 B1
6440107 Trombley, III et al. Aug 2002 B1
6467732 Tsukahara Oct 2002 B2
6481756 Field et al. Nov 2002 B1
6482188 Rogers et al. Nov 2002 B1
6485472 Richmond Nov 2002 B1
6486630 Takagi Nov 2002 B2
6491668 Paradis Dec 2002 B1
6508807 Peters Jan 2003 B1
6520932 Taylor Feb 2003 B2
6536805 Matkovich Mar 2003 B2
6537258 Guala Mar 2003 B1
6539248 Moroski Mar 2003 B1
6541802 Doyle Apr 2003 B2
6543745 Enerson Apr 2003 B1
6544236 Cragg et al. Apr 2003 B1
6569118 Johnson et al. May 2003 B2
6569125 Jepson et al. May 2003 B2
RE38145 Lynn Jun 2003 E
6572590 Stevens et al. Jun 2003 B1
6572591 Mayer Jun 2003 B2
6572592 Lopez Jun 2003 B1
6581906 Pott et al. Jun 2003 B2
6585229 Cote, Sr. et al. Jul 2003 B2
6595954 Luther et al. Jul 2003 B1
6595964 Finley et al. Jul 2003 B2
6599273 Lopez Jul 2003 B1
6605076 Jepson et al. Aug 2003 B1
6609696 Enerson Aug 2003 B2
6620119 Utterberg et al. Sep 2003 B1
6626418 Kiehne Sep 2003 B2
6634033 Mizuno et al. Oct 2003 B2
6635044 Lopez Oct 2003 B2
6638244 Reynolds Oct 2003 B1
6638258 Schwartz et al. Oct 2003 B2
6651956 Miller Nov 2003 B2
6655655 Matkovich et al. Dec 2003 B1
6666839 Utterberg et al. Dec 2003 B2
6669673 Lopez Dec 2003 B2
6669681 Jepson et al. Dec 2003 B2
6673059 Guala Jan 2004 B2
6679529 Johnson et al. Jan 2004 B2
6681810 Weston Jan 2004 B2
6682509 Lopez Jan 2004 B2
6695817 Fangrow, Jr. Feb 2004 B1
6699222 Jones et al. Mar 2004 B1
6706022 Leinsing et al. Mar 2004 B1
6716187 Jorgensen et al. Apr 2004 B1
6716189 Jarvik et al. Apr 2004 B1
6722705 Korkor Apr 2004 B2
6723074 Halseth Apr 2004 B1
6726651 Robinson et al. Apr 2004 B1
6726672 Hanly et al. Apr 2004 B1
6730883 Brown et al. May 2004 B2
6745998 Doyle Jun 2004 B2
6746438 Arnissolle Jun 2004 B1
6755391 Newton et al. Jun 2004 B2
6758833 Lopez Jul 2004 B2
6770051 Hughes et al. Aug 2004 B2
6802490 Leinsing et al. Oct 2004 B2
6802836 Bouphavichith et al. Oct 2004 B2
6808161 Hishikawa Oct 2004 B1
6808509 Davey Oct 2004 B1
6811139 Hishikawa Nov 2004 B2
6814726 Lauer Nov 2004 B1
6827709 Fujii Dec 2004 B2
6827710 Mooney et al. Dec 2004 B1
6834842 Houde Dec 2004 B2
6840501 Doyle Jan 2005 B2
6843513 Guala Jan 2005 B2
6866656 Tingey et al. Mar 2005 B2
6869426 Ganem Mar 2005 B2
6871087 Hughes et al. Mar 2005 B1
6874522 Anderson et al. Apr 2005 B2
6878905 Brown et al. Apr 2005 B2
6880801 Matkovich et al. Apr 2005 B2
6883778 Newton et al. Apr 2005 B1
6893056 Guala May 2005 B2
6902207 Lickliter Jun 2005 B2
6908459 Harding et al. Jun 2005 B2
6911025 Miyahara Jun 2005 B2
6916309 Fangrow, Jr. Jul 2005 B2
6918500 Okiyama Jul 2005 B2
6932795 Lopez et al. Aug 2005 B2
6953450 Baldwin et al. Oct 2005 B2
6955669 Curutcharry Oct 2005 B2
6960198 Sarmiento Nov 2005 B2
6964406 Doyle Nov 2005 B2
6969381 Voorhees Nov 2005 B2
6972001 Emig et al. Dec 2005 B2
6974446 Hommann et al. Dec 2005 B2
6994315 Ryan et al. Feb 2006 B2
7004934 Vaillancourt Feb 2006 B2
7008406 Mayer Mar 2006 B2
7014169 Newton et al. Mar 2006 B2
7025744 Utterberg et al. Apr 2006 B2
7033339 Lynn Apr 2006 B1
7037302 Vaillancourt et al. May 2006 B2
7041087 Henderson et al. May 2006 B2
7044441 Doyle May 2006 B2
7044937 Kirwan et al. May 2006 B1
7081600 Brown et al. Jul 2006 B2
7083605 Miyahara Aug 2006 B2
7090191 Matkovich et al. Aug 2006 B2
7097209 Sparrman et al. Aug 2006 B2
7100891 Doyle Sep 2006 B2
7104520 Leinsing et al. Sep 2006 B2
RE39334 Lynn Oct 2006 E
7114701 Peppel Oct 2006 B2
7118560 Bonaldo Oct 2006 B2
7128348 Kawamura et al. Oct 2006 B2
7137974 Almasian et al. Nov 2006 B2
7140592 Mitchell Dec 2006 B2
7153296 Mitchell Dec 2006 B2
7156826 Ishii et al. Jan 2007 B2
7160272 Eyal et al. Jan 2007 B1
RE39499 Racz Feb 2007 E
7172572 Diamond et al. Feb 2007 B2
7174923 Schorn et al. Feb 2007 B2
7175615 Hanly et al. Feb 2007 B2
7182313 Doyle Feb 2007 B2
7184825 Leinsing et al. Feb 2007 B2
7396348 Newton et al. Jul 2008 B2
20010045539 Doyle Nov 2001 A1
20010049508 Fangrow et al. Dec 2001 A1
20010051791 Azzolini Dec 2001 A1
20010051793 Weston Dec 2001 A1
20020007157 Azzolini Jan 2002 A1
20020024036 Rohrbough et al. Feb 2002 A1
20020032433 Lopez Mar 2002 A1
20020038114 Segura Mar 2002 A1
20020062106 Chu et al. May 2002 A1
20020082586 Finley et al. Jun 2002 A1
20020099360 Bierman Jul 2002 A1
20020108614 Schultz Aug 2002 A1
20020115981 Wessman Aug 2002 A1
20020115984 Guala Aug 2002 A1
20020117645 Kiehne Aug 2002 A1
20020128595 Weston et al. Sep 2002 A1
20020128607 Haury et al. Sep 2002 A1
20020133124 Leinsing et al. Sep 2002 A1
20020138047 Lopez Sep 2002 A1
20020143300 Trombley et al. Oct 2002 A1
20020143301 Lopez Oct 2002 A1
20020147429 Cowan et al. Oct 2002 A1
20020147431 Lopez et al. Oct 2002 A1
20020153503 Newton et al. Oct 2002 A1
20020156431 Feith et al. Oct 2002 A1
20020161334 Castellano et al. Oct 2002 A1
20020193752 Lynn Dec 2002 A1
20030028156 Juliar Feb 2003 A1
20030032940 Doyle Feb 2003 A1
20030036735 Jepson et al. Feb 2003 A1
20030050610 Newton et al. Mar 2003 A1
20030060779 Richmond Mar 2003 A1
20030060804 Vaillancourt Mar 2003 A1
20030066978 Enerson Apr 2003 A1
20030066980 Hishikawa Apr 2003 A1
20030085372 Newton May 2003 A1
20030093061 Ganem May 2003 A1
20030098430 Leinsing et al. May 2003 A1
20030105452 Mayer Jun 2003 A1
20030109853 Harding et al. Jun 2003 A1
20030120221 Vaillancourt Jun 2003 A1
20030127620 Houde Jul 2003 A1
20030141477 Miller Jul 2003 A1
20030144626 Hanson et al. Jul 2003 A1
20030144647 Miyahara Jul 2003 A1
20030181850 Diamond et al. Sep 2003 A1
20030181854 Sauvageau Sep 2003 A1
20030183795 Doyle Oct 2003 A1
20030195478 Russo Oct 2003 A1
20030199835 Leinsing et al. Oct 2003 A1
20030208165 Christensen et al. Nov 2003 A1
20030209681 Leinsing et al. Nov 2003 A1
20030216712 Kessler et al. Nov 2003 A1
20030225379 Schaffer et al. Dec 2003 A1
20030236497 Fremming et al. Dec 2003 A1
20040006330 Fangrow Jan 2004 A1
20040019344 Peterson et al. Jan 2004 A1
20040030321 Fangrow Feb 2004 A1
20040068238 Utterberg Apr 2004 A1
20040068239 Utterberg Apr 2004 A1
20040073174 Lopez Apr 2004 A1
20040073176 Utterberg Apr 2004 A1
20040092886 Mayer May 2004 A1
20040102738 Dikeman et al. May 2004 A1
20040111078 Miyahara Jun 2004 A1
20040116869 Heinz et al. Jun 2004 A1
20040122418 Voorhees Jun 2004 A1
20040124388 Kiehne Jul 2004 A1
20040124389 Phillips Jul 2004 A1
20040138641 Patzer Jul 2004 A1
20040162517 Furst et al. Aug 2004 A1
20040162540 Walenciak et al. Aug 2004 A1
20040171993 Bonaldo Sep 2004 A1
20040172006 Bonaldo Sep 2004 A1
20040186458 Hiejima et al. Sep 2004 A1
20040193119 Canaud et al. Sep 2004 A1
20040199126 Harding et al. Oct 2004 A1
20040204699 Hanly et al. Oct 2004 A1
20040206924 Newton et al. Oct 2004 A1
20040210194 Bonnette et al. Oct 2004 A1
20040225274 Jansen et al. Nov 2004 A1
20040227120 Raybuck Nov 2004 A1
20040236314 Saab Nov 2004 A1
20040243065 McConnell et al. Dec 2004 A1
20040243069 Feith et al. Dec 2004 A1
20040243070 Lopez Dec 2004 A1
20040249349 Wentling Dec 2004 A1
20040254534 Bjorkman et al. Dec 2004 A1
20040260243 Rickerd Dec 2004 A1
20040260266 Cuschieri et al. Dec 2004 A1
20050010168 Kendall Jan 2005 A1
20050015070 Delnevo et al. Jan 2005 A1
20050021000 Adair et al. Jan 2005 A1
20050033267 Decaria Feb 2005 A1
20050033268 Decaria Feb 2005 A1
20050033269 Decaria Feb 2005 A1
20050038397 Newton et al. Feb 2005 A1
20050059952 Giuliano et al. Mar 2005 A1
20050087715 Doyle Apr 2005 A1
20050090805 Shaw et al. Apr 2005 A1
20050096585 Schon et al. May 2005 A1
20050107770 Schweikert et al. May 2005 A1
20050119613 Moenning et al. Jun 2005 A1
20050121638 Doyle Jun 2005 A1
20050124935 McMichael Jun 2005 A1
20050124942 Richmond Jun 2005 A1
20050124943 Yang Jun 2005 A1
20050151105 Ryan et al. Jul 2005 A1
20050154372 Minezaki Jul 2005 A1
20050159710 Utterberg Jul 2005 A1
20050165365 Newton et al. Jul 2005 A1
20050171487 Haury et al. Aug 2005 A1
20050209555 Middleton et al. Sep 2005 A1
20050228362 Vaillancourt Oct 2005 A1
20050256460 Rome et al. Nov 2005 A1
20050256461 DiFiore et al. Nov 2005 A1
20050261637 Miller Nov 2005 A1
20050261665 Voorhees Nov 2005 A1
20050267445 Mendels Dec 2005 A1
20060015086 Rasmussen et al. Jan 2006 A1
20060025724 Chen Feb 2006 A1
20060025751 Roy et al. Feb 2006 A1
20060027270 Truitt et al. Feb 2006 A1
20060047251 Bickford-Smith et al. Mar 2006 A1
20060074386 Wollmann Apr 2006 A1
20060089603 Truitt et al. Apr 2006 A1
20060089604 Guerrero Apr 2006 A1
20060089605 Fitzgerald Apr 2006 A1
20060111694 Fukai et al. May 2006 A1
20060129109 Shaw et al. Jun 2006 A1
20060129112 Lynn Jun 2006 A1
20060142735 Whitley Jun 2006 A1
20060149213 Raybuck Jul 2006 A1
20060161115 Fangrow Jul 2006 A1
20060173420 Fangrow Aug 2006 A1
20060178645 Peppel Aug 2006 A1
20060184139 Quigley et al. Aug 2006 A1
20060184140 Okiyama Aug 2006 A1
20060200072 Peppel Sep 2006 A1
20060200095 Steube Sep 2006 A1
20060200096 Fangrow Sep 2006 A1
20060206058 Lopez Sep 2006 A1
20060206059 Lopez Sep 2006 A1
20060211997 Fangrow Sep 2006 A1
20060211998 Fangrow Sep 2006 A1
20060211999 Fangrow Sep 2006 A1
20060212000 Fangrow Sep 2006 A1
20060212001 Fangrow Sep 2006 A1
20060212002 Fangrow Sep 2006 A1
20060212003 Fangrow Sep 2006 A1
20060212005 Fangrow Sep 2006 A1
20060212006 Fangrow et al. Sep 2006 A1
20060217671 Peppel Sep 2006 A1
20060217679 Hanly et al. Sep 2006 A1
20060217683 Patania Sep 2006 A1
20060229571 Peppel Oct 2006 A1
20060229590 Roy Oct 2006 A1
20060264842 Fangrow Nov 2006 A1
20060264843 Fangrow Nov 2006 A1
20060264844 Fangrow Nov 2006 A1
20060264845 Lopez Nov 2006 A1
20060264846 Lopez Nov 2006 A1
20060264847 Lopez Nov 2006 A1
20060264848 Fangrow Nov 2006 A1
20060264890 Moberg et al. Nov 2006 A1
20060264891 Lopez Nov 2006 A1
20060264892 Lopez Nov 2006 A1
20060264894 Moberg et al. Nov 2006 A1
20060264908 Ishii et al. Nov 2006 A1
20060264909 Fangrow Nov 2006 A1
20060264910 Fangrow Nov 2006 A1
20060270999 Fangrow Nov 2006 A1
20060271012 Canaud Nov 2006 A1
20060271015 Mantell Nov 2006 A1
20060271016 Fangrow Nov 2006 A1
20060276757 Fangrow Dec 2006 A1
20060276758 Fangrow Dec 2006 A1
20060287638 Aneas Dec 2006 A1
20060287639 Sharp Dec 2006 A1
20060293629 Cote et al. Dec 2006 A1
20060293640 Greco Dec 2006 A1
20070032775 Niedospial et al. Feb 2007 A1
20070032776 Skinner et al. Feb 2007 A1
20070038189 Bartholomew Feb 2007 A1
20070043334 Guala Feb 2007 A1
20070060898 Shaughnessy et al. Mar 2007 A1
20070060902 Brandenburger et al. Mar 2007 A1
20070060904 Vedrine et al. Mar 2007 A1
20070073242 Andersen et al. Mar 2007 A1
20070078393 Lynch et al. Apr 2007 A1
20070078429 Sharp Apr 2007 A1
20070083157 Belley et al. Apr 2007 A1
20070088252 Pestotnik et al. Apr 2007 A1
20070088292 Fangrow Apr 2007 A1
20070088293 Fangrow Apr 2007 A1
20070088294 Fangrow Apr 2007 A1
20070088313 Zinger et al. Apr 2007 A1
20070088324 Fangrow Apr 2007 A1
20070088325 Fangrow Apr 2007 A1
20070088327 Guala Apr 2007 A1
20070093764 Guerrero Apr 2007 A1
20070100294 Sugita et al. May 2007 A1
20070112311 Harding et al. May 2007 A1
20070112312 Fangrow May 2007 A1
20070112313 Fangrow May 2007 A1
20070112314 Harding et al. May 2007 A1
20070112332 Harding et al. May 2007 A1
20070112333 Hoang et al. May 2007 A1
20070129705 Trombley et al. Jun 2007 A1
20070156112 Walsh Jul 2007 A1
20070156118 Ramsey et al. Jul 2007 A1
Foreign Referenced Citations (22)
Number Date Country
1105959 Jul 1981 CA
855319 Nov 1952 DE
8425197 Oct 1985 DE
3740269 Jun 1989 DE
0114677 Aug 1984 EP
0237321 Sep 1987 EP
0309771 Apr 1989 EP
0367549 Oct 1989 EP
0399119 Nov 1990 EP
0438909 Dec 1990 EP
0446463 Dec 1990 EP
1733749 Dec 2006 EP
2034185 Jun 1980 GB
8601712 Mar 1986 WO
8603416 Jun 1986 WO
9311828 Jun 1993 WO
9721463 Jun 1997 WO
9721464 Jun 1997 WO
9826835 Jun 1998 WO
9958186 Nov 1999 WO
0204065 Jan 2002 WO
03086528 Oct 2003 WO
Related Publications (1)
Number Date Country
20080172005 A1 Jul 2008 US